Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113051 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2RECQLKDM4EMAPTTHRB | |
| SCHEMBL3051431 | 0.95 | KDM4E (0.50) | SMN1; SMN2RECQLKDM4EMAPTTHRB | |
| SCHEMBL3051429 | 0.95 | KDM4E (0.50) | SMN1; SMN2RECQLKDM4EMAPTTHRB | |
| SCHEMBL111288 | 0.93 | KDM4E (0.49) | SMN1; SMN2RECQLKDM4EMAPTTHRB | |
| SCHEMBL110903 | 0.93 | KDM4E (0.49) | SMN1; SMN2RECQLKDM4EMAPTTHRB | |
| SCHEMBL112448 | 0.93 | KDM4E (0.49) | SMN1; SMN2RECQLKDM4EMAPTTHRB | |
| SCHEMBL112449 | 0.93 | KDM4E (0.49) | SMN1; SMN2RECQLKDM4EMAPTTHRB | |
| SCHEMBL111289 | 0.93 | KDM4E (0.49) | SMN1; SMN2RECQLKDM4EMAPTTHRB | |
| SCHEMBL113035 | 0.93 | KDM4E (0.49) | SMN1; SMN2RECQLKDM4EMAPTTHRB | |
| SCHEMBL3050141 | 0.93 | KDM4E (0.49) | SMN1; SMN2RECQLKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC | 2025-08-14 | — | — | US | claimed |
| EP-4561372-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024215786-A2 | COMPOSITIONS AND METHODS FOR IMPROVING AUTOPHAGY ACTIVITY AND INHIBITING DYSFUNCTION | WARRIOR ESSENTIALS, LLC (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024026124-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | PETERSON MATTHEW (US) | 2024-02-01 | — | — | WO | claimed |
| US-20220409526-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | RETINA FOUND OF THE SOUTHWEST (US) | 2022-12-29 | — | — | US | claimed |
| EP-4054553-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | Retina Foundation of the Southwest (US) | 2022-09-14 | — | — | EP | claimed |
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC | 2025-08-14 | — | — | US | disclosed |
| EP-4561372-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024215786-A2 | COMPOSITIONS AND METHODS FOR IMPROVING AUTOPHAGY ACTIVITY AND INHIBITING DYSFUNCTION | WARRIOR ESSENTIALS, LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024026124-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | PETERSON MATTHEW (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20220409526-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | RETINA FOUND OF THE SOUTHWEST (US) | 2022-12-29 | — | — | US | disclosed |
| WO-2010127198-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | disclosed |
| WO-1988006159-A1 | PAULOMYCIN-RELATED COMPOUNDS | THE UPJOHN COMPANY (US) | 1988-08-25 | — | — | WO | disclosed |
| WO-1987003879-A1 | PAULOMYCIN RELATED COMPOUNDS | THE UPJOHN COMPANY (US) | 1987-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | AHCY, MGMT, CBS | SMN1; SMN2 4541/4885RECQL 4310/4885KDM4E 2170/4885 |
| US-20220409526-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | PDE6C, STRA6, PDE6A | SMN1; SMN2 2532/4885RECQL 840/4885KDM4E 3217/4885 |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCOR | SMN1; SMN2 820/4885RECQL 1833/4885KDM4E 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.